Eli Lilly's Lartruvo is being pulled from the market, but patients who are already taking the drug will still have access under new program
Eli Lilly and Co. said Thursday it is working with doctors to ensure patients who are currently receiving Lartruvo, a soft-tissue sarcoma therapy being pulled from the market following the failure of a late-stage trial, will still be able to receive the drug if they have been told of the drug's risks and trial outcomes and wish to continue. The company announced in January that a Phase 3 trial of Lartruvo as a combination therapy with doxorubicin in patients with advanced soft-tissue sarcoma did not improve survival compared with standard of care. The drugmaker is now working on facilitating a smooth withdrawal of the drug from the market for advanced soft tissue sarcoma. Shares of Eli Lilly have gained 2% in the year to date, while the S&P 500 has gained 16.8%.